Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Biochemistry
|
October 21, 2020
Characterization of an Antibody Recognizing the Conserved Inner Core of <i>Pseudomonas aeruginosa</i> Lipopolysaccharides
Stefano Elli, Anna Alekseeva, Boopathy Ramakrishnan, et al.
Kidney International
|
April 28, 2019
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
James R Myette, Toshiki Kano, Hitoshi Suzuki, et al.
Blood Cancer Journal
|
November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu, Bharat Chaganty, Liang Lin, et al.
Cell
|
July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
Luke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Biochemistry
|
October 21, 2020
Characterization of an Antibody Recognizing the Conserved Inner Core of <i>Pseudomonas aeruginosa</i> Lipopolysaccharides
Stefano Elli, Anna Alekseeva, Boopathy Ramakrishnan, et al.
Kidney International
|
April 28, 2019
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
James R Myette, Toshiki Kano, Hitoshi Suzuki, et al.
Blood Cancer Journal
|
November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu, Bharat Chaganty, Liang Lin, et al.
Cell
|
July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
Luke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
Page
of 5